2017
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa
Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infectious Diseases 2017, 4: ofx081. PMID: 28680903, PMCID: PMC5490502, DOI: 10.1093/ofid/ofx081.Peer-Reviewed Original ResearchHIV cure strategiesCure strategiesHuman immunodeficiency virus (HIV) eradicationLifetime antiretroviral therapySustained viral eradicationElimination of HIVStandard of careLifetime costsAntiretroviral therapyViral eradicationHIV cureFatal toxicitySingle interventionVirus eradicationLife expectancyCureLower lifetime costsSingle caseSurvival
2014
The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis
Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, Walensky RP. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLOS Medicine 2014, 11: e1001725. PMID: 25225800, PMCID: PMC4165752, DOI: 10.1371/journal.pmed.1001725.Peer-Reviewed Original ResearchConceptsCare CD4 testIncremental cost-effectiveness ratioCare CD4 testingPOC CD4CD4 testCD4 testingResource-limited settingsHIV diagnosisHIV testingClinical outcomesAntiretroviral therapy (ART) eligibilityPerson lifetime costsLife expectancyLifetime costsCost-effectiveness ratioResource limited settingsCost-effectiveness analysisSensitivity/specificityImmunological stagingLow sensitivity/specificityCost-effective thresholdLaboratory-based testsSurvivalEditors' SummaryOutcomesClinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 66: 294-302. PMID: 24732870, PMCID: PMC4146647, DOI: 10.1097/qai.0000000000000166.Peer-Reviewed Original ResearchConceptsThird-line antiretroviral therapySecond-line antiretroviral therapyIncremental cost-effectiveness ratioAntiretroviral therapyAdherence reinforcementClinical impactSecond-line ART failureLifetime incremental cost-effectiveness ratioRaltegravir-based regimenSecond-line regimenTen-year survivalSubstantial survival benefitCost-effectiveness ratioPrimary outcomeSurvival benefitART failureDrug costsImmediate switchRegimenPatientsTherapyReinforcement interventionSaharan AfricaSurvivalSub-Saharan Africa
2010
Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, Investigators F. Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. PLOS Medicine 2010, 7: e1000382. PMID: 21209794, PMCID: PMC3014084, DOI: 10.1371/journal.pmed.1000382.Peer-Reviewed Original ResearchConceptsHIV treatment guidelinesART initiationTreatment guidelinesStage III/IV diseaseLong-term survival advantageEarly antiretroviral therapy initiationAntiretroviral therapy initiationLife expectancySouth African HIVResource limited settingsProjected life expectancyResource-limited settingsGreater life expectancyART regimensTherapy initiationAfrican HIVGuideline componentsSurvival advantageWHO recommendationsTenofovirRegimensStavudineSurvivalGuidelinesInitiation